Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Revolution Medicines Q3 2026 Results: Net Loss of $407M, Loss Widens

Revolution Medicines reported its first product revenue of $197.6 million for the quarter ended September 30, 2026, following the commercialization of RASONQUE® (daraxonrasib). The company significantly strengthened its balance sheet, ending the period with approximately $3.65 billion in cash and marketable securities, though it continues to operate with a substantial accumulated deficit of $4.37 billion.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue197.60.0
Profit before tax-409.8-305.2
Net income-407.5-305.2
EPS (diluted, $ a share)$-1.90$-1.61

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Operating margin-188.9%
Source

10-Q filed with the SEC, NASDAQ: RVMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Revolution Medicines, Inc.: key numbers

Share price
$166.87Close, Nov 16
Market cap
$36.1B
Shares outstanding
216.29MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Revolution Medicines, Inc.

All →
6:00 PM ET Form 4
Insider Selling

Revolution Medicines CFO Jack Anders Sells $6.72M of Stock

Jack Anders, CFO, sold 35,750 shares of Revolution Medicines, Inc. at $181.04 to $192.84 a share (average $188.10) in 11 transactions, worth $6.72M in total on Nov 11, 2026. Shares held after the trade: 119,216 (-7.7%).

Value
$6.72M
Shares
35,750
Average price
$188.10
Role
CFO
Holding change
-7.7%
Trade date
Nov 11, 2026
4:06 PM ET 8-K
Financial Results

Revolution Medicines Financial Results

Revolution Medicines reported financial results for the third quarter of 2026, highlighted by the U.S. commercial launch of RASONQUE (daraxonrasib) for metastatic pancreatic cancer. The product generated $197.6 million in net revenue during its first five weeks on the market, with over 5,000 unique patients treated. The company also received a positive CHMP opinion for the drug in the European Union.

Term
Q3 2026

“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.”

Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
6:00 PM ET Form 4
Insider Selling

Revolution Medicines Insider Anthony Mancini Sells $432K of Stock

Anthony Mancini sold 2,310 shares of Revolution Medicines, Inc. at $186.99 a share, worth $432K in total on Oct 26, 2026. Shares held after the trade: 39,765 (-5.5%).

Value
$432K
Shares
2,310
Price
$186.99
Holding change
-5.5%
Trade date
Oct 26, 2026
4:32 PM ET 8-K
Loan & Debt

Revolution Medicines $250M Debt Financing with Royalty Pharma Development Funding, LLC

Revolution Medicines drew down a $250 million Tranche A senior secured term loan from Royalty Pharma following the FDA approval of RASONQUE. The loan bears interest at a floating rate of three-month Term SOFR plus 5.75% and is due in full on October 8, 2032. The company also elected not to exercise an option to sell an additional $250 million royalty interest to Royalty Pharma.

Value
$250M
Counterparty
Royalty Pharma Development Funding, LLC
Term
through Oct 2032
6:00 PM ET Form 4
Insider Selling

Revolution Medicines Chief Development Officer Alan B. Sandler Sells $1.28M of Stock

Alan B. Sandler, Chief Development Officer, sold 6,309 shares of Revolution Medicines, Inc. at $200.82 to $204.72 a share (average $202.14) in 5 transactions, worth $1.28M in total on Sep 29, 2026. Shares held after the trade: 52,559 (-0.6%).

Value
$1.28M
Shares
6,309
Average price
$202.14
Role
Chief Development Officer
Holding change
-0.6%
Trade date
Sep 29, 2026
6:00 PM ET Form 4
Insider Selling

Revolution Medicines Director Elizabeth M. Anderson Sells $1.96M of Stock

Elizabeth M. Anderson, Director, sold 10,143 shares of Revolution Medicines, Inc. at $191.85 to $195.15 a share (average $193.04) in 5 transactions, worth $1.96M in total on Sep 22, 2026. Shares held after the trade: 4,333 (-2.3%).

Value
$1.96M
Shares
10,143
Average price
$193.04
Role
Director
Holding change
-2.3%
Trade date
Sep 22, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.